Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain
  • USA - English


News provided by

MediNatura

Sep 01, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Traumeel™ and Zeel™ demonstrated to relieve moderate to severe knee pain better than a placebo in a recent clinical study.
Traumeel™ and Zeel™ demonstrated to relieve moderate to severe knee pain better than a placebo in a recent clinical study.

Chicago, IL (PRWEB) September 01, 2015 -- MediNatura™, the exclusive U.S. importer of osteoarthritis injections Traumeel™ and Zeel™, has recently sponsored an educational workshop for physician assistants (PAs) practicing in orthopedics. The workshop, titled “Treatment of Osteoarthritis Knee Pain with Combined I.A. Injections of Traumeel™ and Zeel™” was held by Dr. Erick Salado, an orthopedic surgeon at South Florida Bone and Joint Institute, Inc. The framework was the annual conference of Physician Assistants in Orthopaedic Surgery (PAOS), held last week in Chicago.[1]

The current treatment possibilities for osteoarthritis knee pain are not without risks. Traumeel™ and Zeel™ injections offer a new option to patients suffering from osteoarthritis knee pain.

Post this

“There are over 300 million patient encounters by PAs per year. Of those patients, over 50 million are seen for musculoskeletal complaints such as osteoarthritis knee pain,” said Stefan Luft, PhD, national director of sales and medical education, MediNatura™. “Every day, PAs are improving the care of patients with osteoarthritis and are adding incredible value to healthcare teams.”

Osteoarthritis knee pain is one of the most common complaints heard by orthopedic PAs, which is why new treatments in the works are raising so many hopes. “We are committed to making our treatments available to as many patients as possible, and it’s only natural to keep PAs up to date when it comes to our clinical research, since they are at the forefront of patient care,” Luft added.

The current treatment possibilities for osteoarthritis knee pain are not without risks. Steroids and nonsteroidal anti-inflammatory drugs (NSAIDs) have potentially severe side effects. For example, use of NSAIDs for more than three months is associated with rates of gastric ulceration between 15% and 35%.[2] The elevated risk for cardiovascular events associated with NSAIDs recently prompted the US Food and Drug Administration to issue a stronger warning regarding these drugs.[3,4] As well, a recent study published in The BMJ demonstrated a 60% increase in the 30-day risk for intracranial hemorrhage in individuals taking antidepressants plus NSAIDs versus antidepressants alone.[5]

New hope comes from a natural injection treatment that has been demonstrated to relieve moderate to severe knee pain better than a placebo in a recent clinical study while promising an excellent safety profile.[6] Two homeopathic prescription drugs, Traumeel™ and Zeel™, showed efficacy effect sizes consistent with those observed for widely used knee injections of hyaluronic acid (viscosupplementation), corticosteroids, and oral NSAIDs.[7,8]

The mechanism of action of the Traumeel™ and Zeel™ injections is still under investigation, but preclinical studies suggest that these medications regulate inflammation, reducing osteoarthritis knee pain and stiffness in arthritic joints by modulating inflammatory mediators such as TNF-α and supporting cartilage function.[9]

 

Sources
1. http://www.paos.org
2. Bjarnason I. Int J Clin Pract Suppl. 2013;178:37–42. Abstract
3. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm454141.htm Accessed August 13, 2015.
4. Anwar A., John Anwar I., Delafontaine P. Trends Cardiovasc Med. 2015;S1050–1738.
5. Shin J. Y., Park M. J., Lee S. H., et al. BMJ. 2015;351:h3517.
6. Lozada, C., del Rio, E., Reitberg, D. P., Smith, R., Kahn, C., and Moskowitz, R. W. Arth Rheumat 66 (10) Suppl.: S1266 (Abstr 2896)
7. Bannuru et al. Ann Intern Med; 162: 1/6/15:p46–54
8. Lozada, C., del Rio, E., Reitberg, D. P., Smith, R., Kahn, C., and Moskowitz, R. W. Ann Rheum Dis 2015 EULAR. Abstract 4268
9. Porozov S., Cahalon L., Weiser M., Branski D., Lider O., Oberbaum M. Clinical and Developmental Immunology. 2004;11(2):143–149.

About MediNatura™, Inc.
MediNatura™, Inc., is headquartered in greater Philadelphia and operates a factory and product development facility in Albuquerque, New Mexico. MediNatura™ provides Rx and OTC medicines with exceptionally safe side-effect profiles. It does this by using active ingredients predominantly from natural sources. For more information on MediNatura™ and its products, please visit http://www.medinatura.com.

Call weekdays 8am–5pm MST (1-844-633-4628), or email info(at)MediNatura(dot)com.

Jessly Raj, MediNatura, +1 (505) 363-0540, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.